Sickle Cell Therapy

FDA Sets December Deadline for Vertex and CRISPR’s Sickle Cell Therapy

The US Food and Drug Administration (FDA) has initiated a priority review of exagamglogene autotemcel (exa-cel), a therapy developed by ...